Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proton Pump Inhibitor for Hearing Loss in SLC26A4 Mutation
NCT00789061Phase 3Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Aug 2006
- Primary completion
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lansoprazole in hearing loss (2 arms), sponsored by National Taiwan University Hospital. Primary endpoint: Decrease in attack frequency or improvement of hearing loss at 3 years. Status: unknown.
02
Drugs
lansoprazole
03
Conditions
hearing loss
Beyond the preview
Go deeper on NCT00789061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00789061.